Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine

Cancer statistics, 2020

Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2020 · 21.4K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

James L. Mohler, Emmanuel S. Antonarakis, Andrew J. Armstrong et al. · Journal of the National Comprehensive Cancer Network · 2019 · 1.6K citations · Full text

Medicine, Oncology, Urology +17

Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

Al B. Benson, Alan P. Venook, Lynette Cederquist et al. · Journal of the National Comprehensive Cancer Network · 2017 · 1.4K citations · Full text

Medicine, Molecular Medicine, Oncology +17

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Timothy D. Gilligan, Daniel W. Lin, Rahul Aggarwal et al. · Journal of the National Comprehensive Cancer Network · 2019 · 451 citations

Medicine, Oncology, Surgery +16

Hydrolysis of Capecitabine to 5′-Deoxy-5-fluorocytidine by Human Carboxylesterases and Inhibition by Loperamide

Sara K. Quinney, S. Sanghani, Wilhelmina I. Davis et al. · Journal of Pharmacology and Experimental Therapeutics · 2005 · 184 citations

Medicine, Oncology, Pharmacology +14